Latest Ratios: P/E Ratio -1.1x · EV/EBITDA N/A · ROE -74.0%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $234M | $13M | $12M | $19M | $46M | $161M | — | — | — |
| Enterprise Value | $226M | $6M | $6M | $13M | $36M | $156M | — | — | — |
| P/E Ratio → | -1.11 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.61 | 0.72 | 0.32 | 0.30 | 0.44 | 1.10 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.0% | -74.0% | -58.4% | -40.5% | -38.9% | -45.3% | -126.5% | — | — |
| ROA | -61.8% | -61.8% | -50.4% | -35.4% | -35.8% | -42.1% | -177.5% | -1091.6% | -704.8% |
| ROIC | -76.6% | -76.6% | -52.6% | -36.6% | -31.3% | -39.7% | — | — | — |
| ROCE | -76.1% | -76.1% | -58.3% | -41.6% | -38.1% | -45.5% | -117.2% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.10 | 0.10 | 0.08 | 0.02 | 0.04 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.39 | -0.16 | -0.10 | -0.09 | -0.03 | -1.00 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -657.91 | -657.91 | -334.08 | -256.69 | -220.86 | -53.92 | -10.90 | -6.42 | -38.87 |
Net cash position: cash ($9M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.06 | 5.06 | 7.70 | 11.92 | 11.98 | 30.38 | 4.16 | 0.02 | 0.48 |
| Quick Ratio | 5.06 | 5.06 | 7.70 | 11.92 | 11.98 | 30.38 | 4.16 | 0.02 | 0.48 |
| Cash Ratio | 4.98 | 4.98 | 7.59 | 11.65 | 11.82 | 30.19 | 3.44 | 0.01 | 0.25 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 53.7% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 53.7% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $1M | $1M | $1M | $2M | $1M | $2M | $1M | $1M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FTH stock.
Faeth Therapeutics, Inc.'s current P/E ratio is -1.1x. This places it at the 50th percentile of its historical range.
Faeth Therapeutics, Inc.'s return on equity (ROE) is -74.0%. The historical average is -63.9%.
Based on historical data, Faeth Therapeutics, Inc. is trading at a P/E of -1.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Cash burn versus thin liquidity
Metrics are mathematically derived from official filings.
Book-Value Discount Reflects Impaired Earnings
Based on reported figures, FTH trades at 0.61 times book value while carrying a negative trailing P/E of -1.11, a combination that signals the market is pricing the balance sheet rather than any earnings stream it can currently demonstrate.
A sub-1.0 price-to-book multiple against a deeply negative earnings base suggests investors are discounting reported equity of roughly $167.9M, likely because the accumulated deficit of -$489.8M and recurring cash burn cast doubt on how much of that book value can be converted into shareholder returns. Forward earnings and EV-based multiples are unavailable, so the valuation cannot be benchmarked against own history or growth expectations. Relative to peers such as IMVT and CRVS, which trade at much higher price-to-book multiples, FTH's discount appears to reflect a weaker perceived capacity to monetize its asset base, though this inference warrants further investigation as peer earnings profiles differ materially.
Leverage Minimal, Coverage Metrics Meaningless
According to reported figures, FTH's debt-to-equity ratio fell to 0.00 by 2026Q3 as total debt declined from $5.0M to $145.0K, but interest coverage remains deeply negative, so debt service capacity cannot be meaningfully measured.
Near-zero leverage removes debt covenants and refinancing as a near-term pressure point, which is a constructive feature for a pre-profit company. However, interest coverage has been negative across the series, reaching -1571.33 in 2025Q4, which reflects an absence of operating earnings rather than a debt-service burden and therefore offers little insight into solvency. The more relevant risk is equity-funded survival, since leverage is low but operating losses continue to erode the capital base. Investors should monitor how the remaining cash reserve is depleted relative to ongoing burn rather than rely on debt ratios.
Current Ratio Overstates Practical Liquidity
As reported in financial statements, FTH's current ratio of 16.12 in 2026Q3 appears strong, yet cash of $14.2M set against a $170.2M net loss in 2026Q1 suggests the headline liquidity figure may overstate the practical runway available.
The current ratio has been volatile, moving from 5.06 in 2025Q4 to 19.69 in 2026Q2 and 16.12 in 2026Q3, and such swings likely reflect the timing of capital raises rather than a stable operating liquidity profile. Because quarterly cash burn appears to run in the range of several million dollars in operating outflows, a high current ratio on a small cash base implies limited buffer against continued losses. Under severe stress, the position would depend on whether equity markets remain open for further raises, a dependency that the reported figures alone cannot confirm.
Working Capital Metrics Lack Operating Substance
Based on reported figures, FTH's receivable, inventory, and payable cycle metrics are largely unavailable, with only sporadic DPO and asset turnover readings, so the cash conversion cycle cannot be assessed with confidence.
The absence of consistent DSO, DIO, and CCC data is consistent with a pre-commercial oncology business that has no meaningful revenue or inventory base, so working capital efficiency is not a relevant lens for this company at present. Sporadic payable readings, such as DPO of 13,895 days in 2026Q3, are not economically interpretable and likely reflect minimal operating activity rather than supplier leverage. Analysts should not infer supplier or customer dynamics from these figures and should instead focus on the cash runway.
Misapplied Current Ratio Obscures Cash Runway
The current ratio is the metric most commonly misapplied to a pre-revenue biotech like FTH, and according to reported balance sheet data its 16.12 reading in 2026Q3 may obscure a thin cash base relative to quarterly burn.
A high current ratio is often read as evidence of solvency, but for a clinical-stage company its numerator is dominated by cash that is being consumed by R&D and stock-compensation-heavy SG&A, so the ratio reflects timing of financing rather than operating strength. A more useful lens is months of cash runway, calculated as cash on hand divided by average quarterly operating cash outflow, combined with the trajectory of equity raises. Stock-based compensation rising to $12.9M in 2026Q1 further suggests that reported cash burn may understate economic cost, which warrants further investigation.